Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of YP-18 (tazobactam/piperacillin) in Intra-Abdominal Infections
jRCT2080221068Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of piperacillin + tazobactam in Intra-abdominal infection (IAI), surgical site infection (SSI), acute cholecystitis and 3 more, sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
piperacillin + tazobactam
03
Conditions
Intra-abdominal infection (IAI)surgical site infection (SSI)acute cholecystitisacute cholangitisPelviabdominal infection
Beyond the preview
Go deeper on jRCT2080221068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221068.